{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:29:23Z","timestamp":1786724963658,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The aim of this study was to evaluate and update the effects of immunosuppressive therapy on heart failure outcomes in patients aged\u00a016\u00a0years or older with biopsy-proven inflammatory myocardial disease. We performed a systematic review and an aggregate data meta-analysis of studies evaluating the effects of such therapy in acute and chronic myocarditis or inflammatory dilated cardiomyopathy. Studies were chosen based on criteria related to clinical relevance for therapeutic decisions and measured outcomes in left ventricular ejection fraction (LVEF) and New York Heart Association classification (NYHA) at 3, 6, and 12\u00a0months. Data sources included PubMed, Embase, Ovid, and ClinicalTrials.gov, with manual reference checks. Data extraction and risk-of-bias assessments were performed by two independent reviewers. We used a random-effects model and assessed heterogeneity with I\n                    <jats:sup>2<\/jats:sup>\n                    and \u03c4\n                    <jats:sup>2<\/jats:sup>\n                    statistics. . Seven eligible studies with a total of 594 patients were included, that investigated clinical course of acute and chronic myocarditis and inflammatory dilated cardiomyopathy. At 3\u00a0months, the pooled standardized mean difference (SMD) for LVEF was 0.97 (95% CI \u20130.05 to 1.99;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05). At 6\u00a0months, the pooled SMD was 0.48 (95% CI \u20131.31 to 2.28), and at 12\u00a0months, \u20130.01 (95% CI \u20131.65 to 1.62). For NYHA classification, pooled SMDs were 0.02 (95% CI \u20130.21 to 0.25) at 3\u00a0months and \u20130.22 (95% CI \u20131.56 to 1.11) at 12\u00a0months. In all cases, confidence intervals crossed zero. Heterogeneity remained high (I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200992\u201397%), reflecting substantial variability across studies. In patients with acute or chronic myocarditis or inflammatory dilated cardiomyopathy, immunosuppressive therapy does not improve key echocardiographic or clinical parameters when adding new data from randomized controlled trials (RCTs). High heterogeneity suggests variability in patient populations and protocols, highlighting the need for well-designed RCTs. There is still no evidence to support routine endomyocardial biopsy in non-severe disease, as it will not impact symptomatic treatment, even if inflammation is present.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-25165-3","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:30:44Z","timestamp":1761229844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunosuppressive therapy in patients with biopsy-proven inflammatory myocardial disease: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Bruno","family":"Stautner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Tkaczyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sorg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Suchocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa Anita","family":"Jankowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"25165_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","volume":"18","author":"C Tsch\u00f6pe","year":"2021","unstructured":"Tsch\u00f6pe, C. et al. Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. Nat. Rev. Cardiol. 18, 169\u2013193 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"25165_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","volume":"93","author":"P Richardson","year":"1996","unstructured":"Richardson, P. et al. Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93, 841\u2013842 (1996).","journal-title":"Circulation"},{"key":"25165_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.carpath.2011.10.001","volume":"21","author":"O Leone","year":"2012","unstructured":"Leone, O. et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc. Pathol. 21, 245\u2013274 (2012).","journal-title":"Cardiovasc. Pathol."},{"key":"25165_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","volume":"59","author":"I Kindermann","year":"2012","unstructured":"Kindermann, I. et al. Update on myocarditis. J. Am. Coll. Cardiol. 59, 779\u2013792 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"25165_CR5","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/eurheartj\/ehm076","volume":"28","author":"ALP Caforio","year":"2007","unstructured":"Caforio, A. L. P. et al. A prospective study of biopsy-proven myocarditis: Prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur. Heart J. 28, 1326\u20131333 (2007).","journal-title":"Eur. Heart J."},{"key":"25165_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/00005792-199907000-00005","volume":"78","author":"GM Felker","year":"1999","unstructured":"Felker, G. M. et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1278 patients. Medicine (Baltimore) 78, 270\u2013283 (1999).","journal-title":"Medicine (Baltimore)"},{"key":"25165_CR7","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1001\/jama.296.15.1867","volume":"296","author":"JA Towbin","year":"2006","unstructured":"Towbin, J. A. et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296, 1867\u20131876 (2006).","journal-title":"JAMA"},{"key":"25165_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ehf2.14585","volume":"11","author":"Z Lei","year":"2024","unstructured":"Lei, Z. et al. Identification of the communal pathogenesis and immune landscape between viral myocarditis and dilated cardiomyopathy. ESC Heart Fail. 11, 282\u2013292 (2024).","journal-title":"ESC Heart Fail."},{"key":"25165_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ehf2.14172","volume":"10","author":"N Amelotti","year":"2023","unstructured":"Amelotti, N. et al. What\u2019s behind your eosinophilic myocarditis? A case of Churg-Strauss syndrome diagnosed during acute heart failure. ESC Heart Fail. 10, 709\u2013715 (2023).","journal-title":"ESC Heart Fail."},{"key":"25165_CR10","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.amjcard.2008.07.041","volume":"102","author":"LTJ Cooper","year":"2008","unstructured":"Cooper, L. T. J. et al. Usefulness of immunosuppression for giant cell myocarditis. Am. J. Cardiol. 102, 1535\u20131539 (2008).","journal-title":"Am. J. Cardiol."},{"key":"25165_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"key":"25165_CR12","unstructured":"Team, R. C. R: A language and environment for statistical computing (2024)."},{"key":"25165_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ejhf.2082","volume":"23","author":"MR Hazebroek","year":"2021","unstructured":"Hazebroek, M. R. et al. Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: A prospective, double-blind, randomized, placebo-controlled clinical trial. Eur. J. Heart Fail. 23, 302\u2013309 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"25165_CR14","first-page":"37","volume":"123","author":"H Poloczkova","year":"2022","unstructured":"Poloczkova, H. et al. Effect of immunosuppressive therapy in inflammatory cardiomyopathy: Data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial. Bratisl Lek Listy 123, 37\u201343 (2022).","journal-title":"Bratisl Lek Listy"},{"key":"25165_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/01.CIR.104.1.39","volume":"104","author":"R Wojnicz","year":"2001","unstructured":"Wojnicz, R. et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: Two-year follow-up results. Circulation 104, 39\u201345 (2001).","journal-title":"Circulation"},{"key":"25165_CR16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","volume":"30","author":"A Frustaci","year":"2009","unstructured":"Frustaci, A., Russo, M. A. & Chimenti, C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: The TIMIC study. Eur. Heart J. 30, 1995\u20132002 (2009).","journal-title":"Eur. Heart J."},{"key":"25165_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00392-016-0986-9","volume":"105","author":"H-P Schultheiss","year":"2016","unstructured":"Schultheiss, H.-P. et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-\u03b2 treatment in patients with chronic viral cardiomyopathy. Clin. Res. Cardiol. 105, 763\u2013773 (2016).","journal-title":"Clin. Res. Cardiol."},{"key":"25165_CR18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1056\/NEJM198910193211601","volume":"321","author":"JE Parrillo","year":"1989","unstructured":"Parrillo, J. E. et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N. Engl. J. Med. 321, 1061\u20131068 (1989).","journal-title":"N. Engl. J. Med."},{"key":"25165_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/NEJM199508033330501","volume":"333","author":"JW Mason","year":"1995","unstructured":"Mason, J. W. et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med. 333, 269\u2013275 (1995).","journal-title":"N. Engl. J. Med."},{"key":"25165_CR20","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/ehf2.12762","volume":"7","author":"P Timmermans","year":"2020","unstructured":"Timmermans, P. et al. Prednisone and azathioprine in patients with inflammatory cardiomyopathy: Systematic review and meta-analysis. ESC Heart Fail. 7, 2278\u20132296 (2020).","journal-title":"ESC Heart Fail."},{"key":"25165_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10741-018-9709-9","volume":"23","author":"M-P Winter","year":"2018","unstructured":"Winter, M.-P. et al. Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis. Heart Fail. Rev. 23, 573\u2013581 (2018).","journal-title":"Heart Fail. Rev."},{"key":"25165_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2459\/JCM.0000000000000134","volume":"17","author":"C Lu","year":"2016","unstructured":"Lu, C. et al. Immunosuppressive treatment for myocarditis: A meta-analysis of randomized controlled trials. J. Cardiovasc. Med. (Hagerstown) 17, 631\u2013637 (2016).","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"25165_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102710","volume":"20","author":"C Cheng","year":"2021","unstructured":"Cheng, C. et al. Efficacy of immunosuppressive therapy in myocarditis: A 30-year systematic review and meta analysis. Autoimmun. Rev. 20, 102710 (2021).","journal-title":"Autoimmun. Rev."},{"key":"25165_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/01.CIR.0000155616.07901.35","volume":"111","author":"U K\u00fchl","year":"2005","unstructured":"K\u00fchl, U. et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with \u2018idiopathic\u2019 left ventricular dysfunction. Circulation 111, 887\u2013893 (2005).","journal-title":"Circulation"},{"key":"25165_CR25","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"ALP Caforio","year":"2013","unstructured":"Caforio, A. L. P. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 34, 2636\u20132648 (2013).","journal-title":"Eur. Heart J."},{"key":"25165_CR26","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/ejhf.1560","volume":"21","author":"C Tsch\u00f6pe","year":"2019","unstructured":"Tsch\u00f6pe, C., Elsanhoury, A., Schlieker, S., Van Linthout, S. & K\u00fchl, U. Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence. Eur. J. Heart Fail. 21, 1468\u20131469 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"25165_CR27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1253\/circj.CJ-88-0008","volume":"75","author":"JCS Joint Working Group","year":"2011","unstructured":"JCS Joint Working Group. Guidelines for Diagnosis and Treatment of Myocarditis (JCS 2009). Circ. J. 75, 734\u2013743 (2011).","journal-title":"Circ. J."},{"key":"25165_CR28","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(11)60648-X","volume":"379","author":"S Sagar","year":"2012","unstructured":"Sagar, S., Liu, P. P. & Cooper, L. T. J. Myocarditis. Lancet 379, 738\u2013747 (2012).","journal-title":"Lancet"},{"key":"25165_CR29","first-page":"3","volume":"1","author":"HT Aretz","year":"1987","unstructured":"Aretz, H. T. et al. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1, 3\u201314 (1987).","journal-title":"Am. J. Cardiovasc. Pathol."},{"key":"25165_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2008","unstructured":"Elliott, P. et al. Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 29, 270\u2013276 (2008).","journal-title":"Eur. Heart J."},{"key":"25165_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1161\/CIRCULATIONAHA.108.769489","volume":"118","author":"I Kindermann","year":"2008","unstructured":"Kindermann, I. et al. Predictors of outcome in patients with suspected myocarditis. Circulation 118, 639\u2013648 (2008).","journal-title":"Circulation"},{"key":"25165_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281296","volume":"18","author":"M-J Kim","year":"2023","unstructured":"Kim, M.-J. et al. 10-year survival outcome after clinically suspected acute myocarditis in adults: A nationwide study in the pre-COVID-19 era. PLoS ONE 18, e0281296 (2023).","journal-title":"PLoS ONE"},{"key":"25165_CR33","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1093\/eurheartj\/ehac348","volume":"43","author":"C Chimenti","year":"2022","unstructured":"Chimenti, C., Russo, M. A. & Frustaci, A. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur. Heart J. 43, 3463\u20133473 (2022).","journal-title":"Eur. Heart J."},{"key":"25165_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-3-030-35276-9_14","volume-title":"Myocarditis: Pathogenesis, Diagnosis and Treatment","author":"A Frustaci","year":"2020","unstructured":"Frustaci, A. & Chimenti, C. Immunosuppressive therapy in myocarditis: lessons from clinical trials and future perspectives. In Myocarditis: Pathogenesis, Diagnosis and Treatment (ed. Caforio, A. L. P.) 261\u2013267 (Springer International Publishing, 2020). https:\/\/doi.org\/10.1007\/978-3-030-35276-9_14."},{"key":"25165_CR35","unstructured":"Higgins, J. P. T. et al. Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.5 (updated August 2024), Cochrane (2024)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25165-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:30:46Z","timestamp":1761229846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25165-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25165"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25165-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u00a0M.T. reports personal fees from Eidos Therapeutics and Alnylam Pharmaceuticals (as a sub-investigator in clinical trials); personal fees from Takeda; travel and accommodation expenses covered by Pfizer; and accommodation expenses covered by Polpharma, outside the submitted work.\u00a0E.J. reports honoraria for lectures and participation in advisory boards from the following companies: AstraZeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Bayer, Vifor Pharma, Pharmacosmos, Swixx Biopharma, Ewopharma, Novartis, Servier, Pfizer, Zoll, Takeda, Sanofi, Amicus, Medison.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37173"}}